Name: Fabrizio Bianchi
University and Training: MSc in Biological Sciences (University of Milan), PhD in molecular and biological sciences (University of Milan).
Work experience: He worked as postdoctoral fellow at the FIRC Institute for Molecular Oncology (IFOM), Milan (Italy), and then at the Program of Molecular Medicine of the European Institute of Oncology (Milan). He was a visiting scientist at the Nuffield Department of Clinical and Laboratory Sciences at University of Oxford. Since 2016 he has been the Head of the Cancer Biomarkers Unit at the Research Hospital (IRCCS) Casa Sollievo della Sofferenza. He has several years of research experience in the fields of cancer genomics and biomarkers development, particularly in the field of circulating miRNAs, cancer gene expression profile and computational biology. He has contributed to the identification of a serum circulating miRNA-signature for lung cancer early detection, which was patented and transferred to a SME (Gensignia Ltd). He is inventor of international patents regarding diagnostic and prognostic tools for lung cancer screening (US8747867B2; US20150057159A1; US20160068913A1). He is an active member of the American Association for Cancer Research (AACR), the European Association for Cancer Research (EACR), the International Association for the Study of Lung Cancer (IASLC), the Italian Society for Cancer Research (AIRC), and the Italian Society of Cancerology (SIC), where he holds the positions of secretary and member of the steering committee.
Scientific area of interest: Transcriptome of solid cancer and cancer biomarkers
Collaborations: Istituto Europeo di Oncologia (IEO, Milan, Italy), IRCCS San Raffaele (Milan), University of Milan, Istituto di Nanotecnologia – CNR in Lecce (Italy), Roma Tre University (Rome, Italy), University of Navarra (Spain), Fred Hutchinson Cancer Research Center (USA).